Tirzepatide

This study evaluated the effects of behavioral therapy with and without the GLP-1 analogue Tirzepatide in patients with morbid obesity and binge eating disorder. The outcomes measured included body weight, binge eating behavior, and harmful coping strategies. Not reported in abstract.

This study examines clinical and neurobehavioral changes following the discontinuation of GLP-1 receptor agonists, specifically tirzepatide. The population, dosage, and specific outcomes measured are not detailed in the abstract. The implications of these changes for patient management are not specified.

This study evaluated the effects of Tirzepatide in patients with Idiopathic Intracranial Hypertension (IIH) compared to a placebo. The trial was conducted at a single center, and specific outcomes related to intracranial pressure were measured. No therapeutic claims are made in the abstract.

Not reported in abstract.

Not reported in abstract.

Not reported in abstract.

This study evaluated the efficacy of once-weekly subcutaneous LY3457263 compared to placebo in participants with Type 2 Diabetes Mellitus who were on a stable dose of Semaglutide or Tirzepatide and had not achieved their HbA1c goal. The specific outcomes and numeric findings are not detailed in the abstract. The study is classified as a Phase 2 trial.

Not reported in abstract.

Not reported in abstract.

This narrative review highlights the importance of understanding the safety and tolerability of glucagon-like peptide-1 receptor agonists, including tirzepatide, but does not provide new data or conclusions.